Interestingly, the TIDE scores of patients in the CLR-high group were significantly higher than those of patients in the CLR-low group, which means that high levels of expression of CLR are significantly associated with a poorer immune escape status in the tumor microenvironment in bladder cancer. The gene discussed is DCLK3; the disease is urinary bladder carcinoma.